Publication date: Available online 23 October 2026 Source: European Urology Oncology Author(s): Kevin Shee, Jonathan J. Song, Janet E. Cowan, C.K. Cornelia Ding, James Nie, Grace Lee, Brendan L. Raizenne, Jeffry P. Simko, Bradley A. Stohr, Nancy Greenland, Deepika Sirohi, Lufan Wang, Carissa E. Chu, Meera Chappidi, Samuel L. Washington, Katsuto Shinohara, Hao G. Nguyen, Matthew R. Cooperberg, Peter R. Carroll
The Nature of Progression on Active Surveillance for Favorable-risk Gleason Grade Group 2 Prostate Cancer. // European Urology Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2588931126002853?dgcid=rss_sd_all
The Nature of Progression on Active Surveillance for Favorable-risk Gleason Grade Group 2 Prostate Cancer. European Urology Oncology. https://www.sciencedirect.com/science/article/pii/S2588931126002853?dgcid=rss_sd_all
“The Nature of Progression on Active Surveillance for Favorable-risk Gleason Grade Group 2 Prostate Cancer.” European Urology Oncology.
@article{article45648,
title = {The Nature of Progression on Active Surveillance for Favorable-risk Gleason Grade Group 2 Prostate Cancer},
journal = {European Urology Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2588931126002853?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...